MeSH | Immune System Diseases (D007154)

Immune System Diseases D007154

Diseases [C] » Immune System Diseases

Description

Disorders caused by abnormal or absent immunologic mechanisms, whether humoral, cell-mediated, or both. MeSH

Hierarchy View

View MeSH Tree View ICD-10 Tree

Subtype Terms (11)

Autoimmune Diseases
133 drugs (85 approved, 48 experimental)

Erythroblastosis, Fetal
4 drugs (3 approved, 1 experimental)

Glomerulonephritis, Membranoproliferative
12 drugs (7 approved, 5 experimental)

Graft vs Host Disease
265 drugs (142 approved, 123 experimental)

Hypersensitivity
169 drugs (80 approved, 89 experimental)

Immune Reconstitution Inflammatory Syndrome
7 approved drugs

Immunologic Deficiency Syndromes
23 drugs (20 approved, 3 experimental)

Immunoproliferative Disorders
16 drugs (8 approved, 8 experimental)

Mast Cell Activation Disorders
3 experimental drugs

Purpura, Thrombocytopenic
8 drugs (7 approved, 1 experimental)

Transfusion Reaction
10 drugs (7 approved, 3 experimental)

Approved Indicated Drugs (1)

deflazacort (emflaza)

Phase 4 Indicated Drugs (27)

acetaminophen (tylenol)

adalimumab (humira)

autologous cd34+ enriched cell fraction that contains cd34+ cells transduced with retroviral vector that encodes for the human adenosine deaminase (ada) cdna sequence from human haematopoietic stem/progenitor (cd34+) cells

azithromycin (zithromax)

etanercept (enbrel)

fentanyl (Innovar)

hepatitis a vaccine, inactivated (vaqta)

ibuprofen (motrin)

immune globulin (human)

inactivated influenza vaccine

inactivated japanese encephalitis vaccine (Ixiaro)

infliximab (remicade)

levobupivacaine (chirocaine)

mesalamine (rowasa)

midazolam (versed)

mycophenolate (myfortic)

pneumococcal 13-valent conjugate vaccine (prevnar 13)

ren shen yang rong tang

rocuronium (zemuron)

tacrolimus (prograf)

Phase 3 Indicated Drugs (12)

allogeneic adipose derived mesenchymal stem cell

bifidobacterium longum

bovine colostrum

dupilumab (dupixent)

lactobacillus paracasei

mycobacterium w vaccine

pentoxifylline (trental)

Phase 2 Indicated Drugs (56)

albumin (Human) (Plasbumin)

allogeneic hematopoietic stem cells (Hemacord)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin)

arsenic trioxide (trisenox)

autologous cd34+ cells

autologous mesenchymal stem cells

benralizumab (fasenra)

bevacizumab (avastin)

capecitabine (xeloda)

cd45-depleted allogenic peripheral blood stem cell

chloroprednisone

cisplatin (platinol)

cyclophosphamide (cytoxan)

denileukin diftitox (ontak)

dexmedetomidine (precedex)

diphenhydramine (benadryl)

doxycycline (vibramycin)

gemcitabine (gemzar)

human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant (Gardasil)

hydroxyurea (hydrea)

levamisole (ergamisol)

lisocabtagene maraleucel

lymphocyte immune globulin, anti-thymocyte globulin (equine) (Atgam)

melphalan (alkeran)

mesna (mesnex)

methadone (methadose)

methylprednisolone (medrol)

naloxone (narcan)

naltrexone (revia)

oxaliplatin (eloxatin)

pamidronate (aredia)

pembrolizumab (keytruda)

pentostatin (nipent)

prednisolone (hydeltra)

prednisone (meticorten)

pyridostigmine bromide (mestinon)

ranitidine (zantac)

rituximab (rituxan)

sirolimus (rapamune)

sodium chloride

tofacitinib (xeljanz)

vedolizumab (entyvio)

Phase 1 Indicated Drugs (25)

6-prenylnaringenin

8-prenyl-naringenin

albuterol (proventil)

allogeneic cord blood

anti-mycoplasma hominis antibodies

bcma/cd19 dual-target car-t

bendamustine (treanda)

cd138 car-t cells

cyclosporine (sandimmune)

dapirolizumab pegol

deferoxamine (desferal)

fetal mesenchymal stem cells

haploidentical natural killer cell

hemopoietic stem cell

ic9-car19 cells

omalizumab (xolair)

sargramostim (leukine)

tolerogenic dendritic cells

Other Experimental Indicated Drugs (49)

autologous umbilical cord blood

bacillus subtilis

bifidobacterium animalis

bovine lactoferrin

choline c11 (choline c-11)

clofarabine (clolar)

desogestrel (Mercilon)

estradiol (progynon depot)

fermented maillard reacted whey protein

hepatitis b vaccine (recombinant) (recombivax)

house dust mite allergen

lactobacillus casei

lactobacillus delbrueckii

lactobacillus plantarum

live attenuated varicella vaccine

medroxyprogesterone (provera)

monoclonal anti-cd303 antibody

norgestrel (Ovral)

omega-3 fatty acids (omacor)

pegvisomant (somavert)

polymethylmetacrylate

salmonella typhi polysaccharide vaccine

seasonal influenza and pneumococcal polysaccharide vaccines

somatropin (protropin)

Streptococcus thermophilus

telbivudine (tyzeka)

Withania somnifera

zinc picolinate

Organization Involved with Phase 4 Indications (11)

Bausch Health Companies

California HIV/AIDS Research Program

Central South University

GlaxoSmithKline

Government of Taiwan

Lund University

University of California, San Francisco

University of Copenhagen

University of Modena and Reggio Emilia

Organization Involved with Phase 3 Indications (12)

Center for International Blood and Marrow Transplant Research

Federal University of Bahia

Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes

La Jolla Pharmaceutical Company

Medical College of Wisconsin

National Cancer Institute (NCI)

National Heart, Lung, and Blood Institute (NHLBI)

University of Minnesota

Organization Involved with Phase 2 Indications (31)

Aarhus University

Blood and Marrow Transplant Clinical Trials Network

Celularity, Inc.

Chinese Academy of Medical Sciences

Fovea Pharmaceuticals

Fudan University

Hellenic Institute for the Study of Sepsis

Indiana University

Juno Therapeutics, Inc.

Linkoping University

Lung Biotechnology PBC

McMaster University

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Pavlov First Saint Petersburg State Medical University

Stem Cells Arabia

Sun Yat-Sen University

Travere Therapeutics, Inc.

University of Athens

University of Bordeaux

University of Leicester

University of Limoges

University of North Carolina at Chapel Hill

University of Toulouse

Washington University in St. Louis

Zhongsh Ophthalmic Center

Organization Involved with Phase 1 Indications (13)

Bellicum Pharmaceuticals

Celal Bayar University

Hammersmith Medicines Research

Hoosier Cancer Research Network

Russian Academy of Medical Sciences

Shanghai Henlius Biotech

Stanford University

The Scientific and Technological Research Council of Turkey

University of Washington

Organization Involved with Other Experimental Indications (12)

Laboratoire français de Fractionnement et de Biotechnologies

McPin Foundation

Medical University of Graz

Nemours Children's Health System

Stanley Medical Research Institute

Thomas Jefferson University

University of Cambridge

University of Helsinki

University of Lille

University of New Mexico

University of Oxford

Hierarchy Tree View

MeSH
ICD-10

UMLS Data

YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.